A First-in-Human Study of RGT-075, a Novel, Orally Bioavailable, Small-Molecule GLP-1 Receptor Agonist, in Healthy Adult Subjects

被引：0
|
作者：
Pirner, Mark A.
Lin, Jing
Liu, Feng
Yao, Lili
Zettler, Marjorie E.
Valacer, David J.
机构：
来源：
DIABETES | 2022年 / 71卷
关键词：
D O I：
10.2337/db22-724-P
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
724-P
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Effects of the GLP-1 receptor agonist liraglutide on human peripheral immune cells from healthy subjects in vitro and in vivo
    Bock, Gerlies
    Prietl, Barbara
    Tauschmann, Martin
    Neuper, Christine
    Graninger, Winfried B.
    Pieber, Thomas R.
    WIENER KLINISCHE WOCHENSCHRIFT, 2012, 124 : 16 - 17
  • [22] A Phase 1, Dose-Escalation Study of a Novel dual GIP and GLP-1 receptor agonist (HS-20094) in Healthy Chinese Subjects
    Xie, R.
    Junyu, X.
    Lu, C.
    Yimin, C.
    Xia, Z.
    DIABETES RESEARCH AND CLINICAL PRACTICE, 2024, 209
  • [23] HD-7671, a Nonpeptide Small Molecule for Orally Available GLP-1 Receptor Agonist, Improves Glucose Tolerance by Increasing Insulin Secretion
    Baek, Myoungki
    Kim, Daehoon
    Kim, Chun Hwa
    Kim, Doo Young
    Choi, Hyo Sun
    Kang, Seung Jun
    Lee, Hankyu
    Lee, Kyuhwan
    DIABETES, 2020, 69
  • [24] Comparative Effects of the Endogenous Agonist Glucagon-Like Peptide-1 (GLP-1)-(7-36) Amide and the Small-Molecule Ago-Allosteric Agent "Compound 2" at the GLP-1 Receptor
    Coopman, Karen
    Huang, Yan
    Johnston, Neil
    Bradley, Sophie J.
    Wilkinson, Graeme F.
    Willars, Gary B.
    JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2010, 334 (03): : 795 - 808
  • [25] A First-in-Human Single/Multiple Ascending Dose Study of ANPA-0073, a Novel Small Molecule G-protein Biased Apelin Receptor Agonist, in Healthy Volunteers
    Bach, M.
    Shi, S.
    Zhang, J.
    Parsley, E.
    Argent, C.
    Guan, C.
    Pelayo, M.
    Ibarra, L.
    Lim, S.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2023, 207
  • [26] First-in-human study to assess the safety, pharmacokinetics, and pharmacodynamics of BMS-986141, a novel, reversible, small-molecule, PAR4 agonist in non-Japanese and Japanese healthy participants
    Merali, Samira
    Wang, Zhaoqing
    Frost, Charles
    Meadows-Shropshire, Stephanie
    Hawthorne, Dara
    Yang, Jing
    Seiffert, Dietmar
    PLATELETS, 2023, 34 (01)
  • [27] Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a Novel Ultra-Long-Acting GLP-1 Receptor Agonist (ZT002) in Healthy Subjects
    Zhang, Yuanyuan
    Xu, Xiusen
    McLendon, Kristi
    Wong, Alex H. L.
    Zhang, Yuying
    Zhang, Xujia
    DIABETES, 2024, 73
  • [28] Efficacy of novel small molecule GLP-1 receptor agonist AZD0186 on glucose stimulated insulin secretion in obese, male non-human primates
    Wallenius, K.
    Van Zuydam, N. R.
    Boianelli, A.
    Davies, G. R.
    Brighton, C. A.
    Wergeni, A. Traff
    Eckernas, D.
    Persson, M.
    Omar, S.
    Pettersen, D.
    Lundqvist, S. A. E.
    Jurva, U.
    Snijder, A.
    Polla, M.
    DIABETOLOGIA, 2023, 66 (SUPPL 1) : S317 - S318
  • [29] First-in-Human study of LMB763, a novel, orally-available farnesoid X receptor agonist that demonstrates modulation of the pharmacodynamic markers FGF19 and C4 in healthy subjects
    Huttner, K.
    Desai, S.
    DeCristofaro, M.
    Laffitte, B.
    Lin, T.
    Chen, J.
    Klickstein, L.
    Badman, M. K.
    JOURNAL OF HEPATOLOGY, 2017, 66 (01) : S425 - S425
  • [30] LAPS GLP/GCG Dual Agonist, HM12525A, Confirmed Prolonged Pharmacokinetics in Healthy Volunteers: A First-in-Human Phase 1 Study
    Kang, Jahoon
    DIABETES, 2015, 64 : A46 - A46
12345